

2020

Association between Parkinson's disease and proton pump inhibitors therapy in older people

Follow this and additional works at: <https://www.biomedicinej.com/biomedicine>



Part of the [Life Sciences Commons](#), and the [Medical Sciences Commons](#)



This work is licensed under a [Creative Commons Attribution 4.0 License](#).

Recommended Citation

Lai, Shih-Wei (2020) "Association between Parkinson's disease and proton pump inhibitors therapy in older people," *BioMedicine*: Vol. 10 : Iss. 3 , Article 1.
DOI: [10.37796/2211-8039.1048](https://doi.org/10.37796/2211-8039.1048)

This Short Communications is brought to you for free and open access by BioMedicine. It has been accepted for inclusion in BioMedicine by an authorized editor of BioMedicine.

Association between Parkinson's disease and proton pump inhibitors therapy in older people

Cover Page Footnote

This study was supported in part by Taiwan Ministry of Health and Welfare Clinical Trial Center (MOHW109-TDU-B-212-114004), MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003-), Tseng-Lien Lin Foundation, Taichung, Taiwan. These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Association between Parkinson's disease and proton pump inhibitors therapy in older people

Shih-Wei Lai ^{a,b}, Kuan-Fu Liao ^{c,d}, Cheng-Li Lin ^e, Chih-Hsueh Lin ^{a,b,*}

^a College of Medicine, China Medical University, Taichung, Taiwan

^b Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

^c College of Medicine, Tzu Chi University, Hualien, Taiwan

^d Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan

^e Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

Abstract

Objectives: The study was to explore the association between Parkinson's disease and proton pump inhibitors use.

Methods: A population-based case-control study was conducted to analyze the 2000-2013 database of Taiwan National Health Insurance Program. In total, there were 4280 participants aged ≥ 65 years with newly diagnosed Parkinson's disease as the case group and 4280 sex- and age-matched participants without Parkinson's disease as the control group. Ever use of proton pump inhibitors was defined as participants who had at least a prescription for proton pump inhibitors before the index date. Never use of proton pump inhibitors was defined as participants who did not have a prescription for proton pump inhibitors before the index date. The odds ratio and 95% confidence interval were used to estimate the association between Parkinson's disease and proton pump inhibitors use by the logistic regression model.

Results: A significant association was detected between Parkinson's disease and proton pump inhibitors use (odds ratio 1.15, 95% confidence interval 1.04-1.27).

Conclusions: An association is found between Parkinson's disease and proton pump inhibitors use in older people. Other real-world data are required to confirm the clinical impact of proton pump inhibitors therapy on the risk of Parkinson's disease.

Keywords: proton pump inhibitors, older people, Parkinson's disease

1. Introduction

Proton pump inhibitors are widely prescribed to treat acid-related disorders of upper gastrointestinal tract. The side effects resulting from long-term use of proton pump inhibitors are of greater concern.[1] One nested case-control study reported that no association could be detected between Alzheimer's Disease and proton pump inhibitors use.[2] In addition, previous studies demonstrated that proton pump inhibitors therapy were associated with increased risk of some comorbidities including pyogenic liver abscess (odds ratio 7.59, 95% confidence interval 5.05-11.4),[3] pulmonary tuberculosis (odds ratio 1.31, 95% confidence interval 1.22-1.41),[4]

and chronic kidney disease (odds ratio 1.41, 95% confidence interval 1.34-1.48).[5] To date, little evidence is available on the association between Parkinson's disease and proton pump inhibitors therapy in Taiwan. Therefore, a case-control study was conducted to investigate this issue.

2. Methods

2.1. Data source and Study subjects

A population-based case-control study was performed to analyze the 2000-2013 database of Taiwan National Health Insurance Program. The Taiwan National Health Insurance Program is a whole-population health insurance system. The program Lunched on 1 March 1995 and it covered more

Received 23 September 2019; accepted 21 November 2019.
Available online 1 September 2020.

* Corresponding author. Department of Family Medicine, China Medical University Hospital, No 2, Yu-De Road, Taichung City, 404, Taiwan. Fax: +886 4 2203 3986.

E-mail address: d5496@mail.cmuh.org.tw (C.-H. Lin).

<https://doi.org/10.37796/2211-8039.1048>

2211-8020/Published by China Medical University 2020. © the Author(s). This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

than 99.7% of the 23 million persons living in Taiwan.[6–8] The details of the program have been found in previous studies.[9–14].

Participants aged ≥ 65 years with newly diagnosed Parkinson's disease were selected as the case group (based on International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 code 332.0). Sex-matched, age-matched, and comorbidities-matched participants without Parkinson's disease were randomly selected as the control group. The index date was defined as the date of each case being diagnosed with Parkinson's disease. Participants who had a history of secondary Parkinsonism before the index date were excluded from the study. To decrease the latency bias, if the first-time prescription for proton pump inhibitors was found ≤ 12 months before the index date, these participants were excluded from the study.

The definition of proton pump inhibitors use was adapted from the previous studies.[15–20] Ever use of proton pump inhibitors was defined as participants who had at least a prescription for proton pump inhibitors before the index date. Never use of proton pump inhibitors was defined as participants who did not have a prescription for proton pump inhibitors before the index date.

2.2. Statistical analysis

The differences of demographic status, proton pump inhibitors use, and comorbidities between the

case group and the control group were compared by using the chi-square test for categorized variables and by the *t*-test for continuous variables. The odds ratio and 95% confidence interval were used to assess the association between Parkinson's disease and proton pump inhibitors use by the logistic regression model. The duration-dependent effect of proton pump inhibitors use associated with the risk of Parkinson's disease was analyzed. All analyses were examined by using SAS statistical software (version 9.2; SAS Institute, Inc., Cary, North Carolina, USA). The results were considered statistically significant if two-tailed *P* values were < 0.05 .

3. Results

There were 4280 participants with Parkinson's disease in the case group and 4280 participants without Parkinson's disease in the control group. Both groups had equal distributions of sex, age, and comorbidities (Table 1). Nearly 50% of the study participants were males. The mean ages (standard deviation) were 76.5 (6.3) years in the case group and 76.4 (6.3) years in the control group, without statistic significance ($P = 0.44$ for *t*-test). The case group had a higher proportion of proton pump inhibitors use than the control group, with statistic significance (23.3% versus 20.9%, $P = 0.008$ for Chi-square test).

Because no variable was significantly associated with Parkinson's disease in the univariable model,

Table 1. Characteristics of cases with Parkinson's disease and controls.

Variable	Controls N = 4280		Cases N = 4280		P value ^a
	n	(%)	n	(%)	
Sex					0.99
Female	2145	(50.1)	2145	(50.1)	
Male	2135	(49.9)	2135	(49.9)	
Age group (years)					0.99
65-74	1818	(42.5)	1818	(42.5)	
75-84	2057	(48.1)	2057	(48.1)	
≥ 85	405	(9.4)	405	(9.4)	
Age (years), mean \pm standard deviation ^b	76.4 \pm 6.3		76.5 \pm 6.3		0.44
Ever use of proton pump inhibitors	895	(20.9)	997	(23.3)	0.008
Exposure duration of proton pump inhibitors (days), mean \pm standard deviation ^b	136.6 \pm 223.2		154.4 \pm 220.1		0.08
Comorbidities					
Alcohol-related disease	90	(2.10)	90	(2.10)	0.99
Cerebrovascular disease	819	(19.1)	819	(19.1)	0.99
Chronic kidney disease	268	(6.26)	268	(6.26)	0.99
Chronic obstructive pulmonary disease	1804	(42.2)	1804	(42.2)	0.99
Diabetes mellitus	801	(18.7)	801	(18.7)	0.99
Hyperlipidemia	1384	(32.3)	1384	(32.3)	0.99
Hypertension	3549	(82.9)	3549	(82.9)	0.99

Data are revealed as the number of participants in each group, with percentages given in parentheses.

^a Chi-square test.

^b *t*-test comparing cases with Parkinson's disease and controls.

the multivariable logistic regression model was not performed. A univariable logistic regression model demonstrated that a significant association was detected between Parkinson's disease and proton pump inhibitors use (odds ratio 1.15, 95% confidence interval 1.04-1.27; Table 2).

In further analysis, there was a significant association between Parkinson's disease and increase in duration for every one month of proton pump inhibitors use (odds ratio 1.02, 95% confidence interval 1.01-1.03; Table 3).

4. Discussion

The present study demonstrated that the odds of proton pump inhibitors therapy were 1.15 times higher in older people with Parkinson's disease versus those without Parkinson's disease. This finding was partially compatible with a case-control study in Denmark showing that proton pump inhibitors therapy before the diagnosis of Parkinson's disease for 5 years or longer remained to be associated with Parkinson's disease (odds ratio 1.23, 95% confidence interval 1.11-1.37).[21] This present study also demonstrated that there was a duration-dependent manner of proton pump inhibitors use on the increased risk of Parkinson's disease. That is,

the longer the proton pump inhibitors use, the greater the risk of Parkinson's disease.

To date, only few studies explored proton pump inhibitors therapy on the risk of Parkinson's disease. We were unable to compare them with each other. Although a significant association was detected between Parkinson's disease and proton pump inhibitors therapy, the causal relationship could not be determined by a case-control design. We suggest that other real-world data are required to illustrate the clinical impact of proton pump inhibitors therapy on the risk of Parkinson's disease.

Some limitations should be discussed. First, proton pump inhibitors and histamine-2 receptor antagonists had similar indications, but they could not be prescribed simultaneously under the Taiwan National Health Insurance Program. Therefore, histamine-2 receptor antagonists were not included in this present study for analysis. However, it indicates a future research direction for the association between Parkinson's disease and histamine-2 receptor antagonists therapy. Second, due to the limitation of the database used, smoking information was not available in the database. Therefore, chronic obstructive pulmonary disease was used for instead. Third, we found that 95.4% of Parkinson's disease cases and 97.6% of controls had ever used non-steroid anti-inflammatory drugs (Table not shown). The proportions were too high. It was not suitable to include non-steroid anti-inflammatory drugs for analysis even if non-steroid anti-inflammatory drugs could be associated with Parkinson's disease. Fourth, proton pump inhibitors could be prescribed only by the endoscopic diagnosis of upper gastro-intestinal diseases in Taiwan. It was less likely to use proton pump inhibitors to treat depression, which was often a prodromal symptom in Parkinson's disease. In spite of the above limitations, the present study has a novel concept that explores the association between Parkinson's disease and proton pump inhibitors therapy.

We conclude that an association is found between Parkinson's disease and proton pump inhibitors use in older people. Other real-world data are required to confirm the clinical impact of proton pump inhibitors therapy on the risk of Parkinson's disease.

Table 2. Odds ratio and 95% confidence interval of Parkinson's disease associated with proton pump inhibitors use and comorbidities by logistical regression model.

Variable	OR	(95%CI)
Sex (male vs. female)	1.00	(0.92,1.09)
Age (every one year)	1.00	(0.99, 1.01)
Ever use of proton pump inhibitors (never use as a reference)	1.15	(1.04, 1.27)
Comorbidities (yes versus no)		
Alcohol-related disease	1.00	(0.74, 1.34)
Cerebrovascular disease	1.00	(0.90, 1.11)
Chronic kidney disease	1.00	(0.84, 1.19)
Chronic obstructive pulmonary disease	1.00	(0.92, 1.09)
Diabetes mellitus	1.00	(0.90, 1.12)
Hyperlipidemia	1.00	(0.91, 1.10)
Hypertension	1.00	(0.89, 1.12)

Because no variable was significantly associated with Parkinson's disease in the univariable model, the multivariable logistic regression model was not performed.

Table 3. Association of Parkinson's disease with cumulative duration of proton pump inhibitors use.

Variable	Case number/control number	Odds ratio (95% CI)
Never use of proton pump inhibitors as a reference	3283/3385	1.00 (reference)
Cumulative duration of proton pump inhibitors use (increase in duration for every one month)	997/895	1.02 (1.01, 1.03)

Because no variable was significantly associated with Parkinson's disease in the univariable model, the multivariable logistic regression model was not performed.

Author contribution

Shih-Wei Lai contributed to the conception of the article, initiated the draft of the article, and has approved the final draft submitted.

Kuan-Fu Liao, Cheng-Li Lin and Chih-Hsueh Lin conducted data analysis.

Shih-Wei Lai and Kuan-Fu Liao contributed equally to the article.

Ethical statement

Insurance reimbursement claims data used in this study were available for public access. Patient identification numbers were scrambled to ensure confidentiality. Patient informed consent was not required. This study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

Acknowledgement

This study was supported in part by the Ministry of Health and Welfare in Taiwan, (MOHW109-TDU-B-212-114004), China Medical University Hospital in Taiwan (DMR-107-192 and DMR-108-089), and MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003). These funding agencies did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- [1] Howden CW. Management of acid-related disorders in patients with dysphagia. *Am J Med* 2004;6:445–85.
- [2] Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No Association Between Proton Pump Inhibitor Use and Risk of Alzheimer's Disease. *Am J Gastroenterol* 2017;112:1802–8.
- [3] Lin HF, Liao KF, Chang CM, Lin CL, Lai SW. Correlation between proton pump inhibitors and risk of pyogenic liver abscess. *Eur J Clin Pharmacol* 2017;73:1019–25.
- [4] Cheng KC, Liao KF, Lin CL, Lai SW. Correlation of Proton Pump Inhibitors with Pulmonary Tuberculosis: A Case-Control Study in Taiwan. *Front Pharmacol* 2017;8:481.
- [5] Hung SC, Liao KF, Hung HC, Lin CL, Lai SW, Lee PC, et al. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a nationwide database-derived case-controlled study. *Fam Pract* 2018;35:166–71.
- [6] Ministry of Health and Welfare Taiwan. Taiwan Health and Welfare Report. 2018. <http://www.mohw.gov.tw>. [Accessed 1 April 2020].
- [7] Liao KF, Lin CL, Lai SW. Association between colorectal cancer and thiazolidinediones administration in a case-control study. *BioMedicine* 2019;9:31–6. Taiwan.
- [8] Lai SW, Lin CL, Liao KF. Hyperuricemia might be an early manifestation of undiagnosed adult leukemia in a population-based cohort study. *BioMedicine* 2020;10:40–4. Taiwan.
- [9] Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. *Medicine* 2010;89:295–9.
- [10] Lin SY, Ju SW, Lin CL, Hsu WH, Lin CC, Ting IW, et al. Air pollutants and subsequent risk of chronic kidney disease and end-stage renal disease: A population-based cohort study. *Environ Pollut* 2020;261:114154.
- [11] Chen CH, Lin CL, Kao CH. The risk of coronary heart disease after diagnosis of gallbladder polyp: a retrospective nationwide population-based cohort study. *Ann Transl Med* 2019;7:753.
- [12] Lin SY, Chen W, Harnod T, Lin CL, Hsu WH, Lin CC, et al. Sleep apnea and risk of traumatic brain injury and associated mortality and healthcare costs: a population-based cohort study. *Ann Transl Med* 2019;7:644.
- [13] Liao KF, Lin CL, Lai SW. Association between allopurinol use and hepatocellular carcinoma in a case-control study in Taiwan. *Eur J Hospital Pharm* 2019;26:258–61.
- [14] Wang IK, Lai SW, Lai HC, Lin CL, Yen TH, Chou CY, et al. Risk of and Fatality from Acute Pancreatitis in Long-Term Hemodialysis and Peritoneal Dialysis Patients. *Perit Dial Int* 2018;38:30–6.
- [15] Cheng KC, Liao KF, Lin CL, Lin CC, Lai SW. Case-control study examining the association between hip fracture risk and statins therapy in old people. *Medicine (Baltimore)* 2019; 98:e17476.
- [16] Cheng KC, Liao KF, Lin CL, Lai SW. Case-Control Study Investigating the Association Between Use of Selective Serotonin Reuptake Inhibitors and Pulmonary Tuberculosis in Taiwan. *Dose Response* 2019;17. 1559325819897165.
- [17] Liao KF, Lin CL, Lai SW. Allopurinol use associated with increased risk of acute myocardial infarction in older people in a case-control study. *Tzu Chi Med J* 2019;31:276–9.
- [18] Hung SC, Liao KF, Hung HC, Lin CL, Lee PC, Hung SJ, et al. Tamoxifen use correlates with increased risk of hip fractures in older women with breast cancer: A case-control study in Taiwan. *Geriatr Gerontol Int* 2019;19:56–60.
- [19] Lin HF, Liao KF, Chang CM, Lin CL, Lai SW, Hsu CY. Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: A case-control study. *Medicine (Baltimore)* 2018;97:e12842.
- [20] Lin HF, Liao KF, Chang CM, Lin CL, Lai SW. Tamoxifen usage correlates with increased risk of Parkinson's disease in older women with breast cancer: a case-control study in Taiwan. *Eur J Clin Pharmacol* 2018;74:99–107.
- [21] Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for *Helicobacter pylori* infection and risk of Parkinson's disease in Denmark. *Eur J Neurol* 2012;19:864–9.